Amarin Corp. (AMRN) Misses Q4 EPS by 3c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations
February 28, 2017 6:00 AM EST$130.1 Million and $38.7 Million Total Revenue for Full Year and Fourth Quarter 2016 Reflect Increases of 59% and 45% Compared to Corresponding Periods in 2015
 REDUCE-IT Cardiovascular Outcomes Study Remains on Schedule to Reach Onset of Final Target Event Near the End of 2017
Management to Host Conference Call at 7:30 a.m. ET Today
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial... More
